Muriel Buri

ORCID

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 7

Top Venues

Blood

The international journal of biostatistics

British journal of haematology

University of Zurich

University of Zurich (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

University of Zurich Sep 01 2016

Switzerland

PhD Candidate :: Computational Biostatistics

Education History

University of Zurich Sep 01 2016

Switzerland

PHD :: Epidemiology, iostatistics and Prevention Institute (EBPI)

University of Zurich Sep 01 2014 - Aug 31 2016

Switzerland

MSC :: Epidemiology, iostatistics and Prevention Institute (EBPI)

Publications

Steven W Pipe, Peter Collins, Christophe Dhalluin, Gili Kenet, Christophe Schmitt, Muriel Buri, Victor Jimenez Yuste, Flora Peyvandi, Guy Aaron Young, Johannes Oldenburg, Maria Elisa Mancuso, Kaan Kavakli, Anna Kiialainen, Sonia Deb, Markus Niggli, Tiffany Chang, Michaela Lehle, Karin C J Fijnvandraat
Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial. Blood 143 (14) (2024)
Steven W Pipe, Peter Collins, Christophe Dhalluin, Gili Kenet, Christophe Schmitt, Muriel Buri, Victor Jimenez Yuste, Flora Peyvandi, Guy Aaron Young, Johannes Oldenburg, Maria Elisa Mancuso, Kaan Kavakli, Anna Kiialainen, Sonia Deb, Markus Niggli, Tiffany Chang, Michaela Lehle, Karin C J Fijnvandraat
Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial. Blood 143 (14) (2024)
Steven W Pipe, Peter Collins, Christophe Dhalluin, Gili Kenet, Christophe Schmitt, Muriel Buri, Victor Jimenez Yuste, Flora Peyvandi, Guy Aaron Young, Johannes Oldenburg, Maria Elisa Mancuso, Kaan Kavakli, Anna Kiialainen, Sonia Deb, Markus Niggli, Tiffany Chang, Michaela Lehle, Karin C J Fijnvandraat
Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial. Blood 143 (14) (2024)
Steven W Pipe, Peter W Collins, Christophe Dhalluin, Gili Kenet, Christophe Schmitt, Muriel Buri, Victor Jimenez Yuste, Flora Peyvandi, Guy Aaron Young, Johannes Oldenburg, Maria Elisa Mancuso, Kaan Kavakli, Anna Kiialainen, Sonia Deb, Markus Niggli, Tiffany Chang, Michaela Lehle, Karin C J Fijnvandraat
Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b, open-label trial. Blood (2023)
Steven W Pipe, Peter W Collins, Christophe Dhalluin, Gili Kenet, Christophe Schmitt, Muriel Buri, Victor Jimenez Yuste, Flora Peyvandi, Guy Aaron Young, Johannes Oldenburg, Maria Elisa Mancuso, Kaan Kavakli, Anna Kiialainen, Sonia Deb, Markus Niggli, Tiffany Chang, Michaela Lehle, Karin C J Fijnvandraat
Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b, open-label trial. Blood (2023)
Jun-Ichi Nishimura, Kensuke Usuki, Julia Ramos, Satoshi Ichikawa, Muriel Buri, Anna Kiialainen, Alexandre Sostelly, Régis Peffault de Latour, Ido Paz-Priel, Alexander Röth
Crovalimab for treatment of patients with paroxysmal nocturnal haemoglobinuria and complement C5 polymorphism: Subanalysis of the phase 1/2 COMPOSER study. British journal of haematology 198 (3) (2022)
Muriel Buri, Torsten Hothorn
Model-based random forests for ordinal regression. The international journal of biostatistics (2020)

Muriel Buri.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Muriel Buri